Every 8-K that Trupanion (TRUP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TRUP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRUP filings page.
Trupanion reported second-quarter 2026 results with total revenue of $392.9 million, up 11% from a year earlier. Subscription business revenue grew to $276.7 million, up 14%. Total enrolled pets were 1,633,131, down 2%, while subscription pets rose 5% to 1,124,548.
GAAP net income for the quarter was $6.8 million, or $0.16 per basic and diluted share, compared with $9.4 million and $0.22 a year ago. Adjusted EBITDA increased to $19.8 million from $16.6 million. Operating cash flow was $21.0 million and free cash flow was $19.2 million, both higher than the prior year.
For the first six months of 2026, revenue was $777.0 million, up 12%, and net income was $11.7 million versus $7.9 million. Adjusted EBITDA was $37.1 million. At June 30, 2026, Trupanion held $398.5 million in cash and short-term investments and had $3.5 million available under its credit facility. In July 2026, an extraordinary $44 million dividend from its insurance subsidiary was approved, and the board authorized a share repurchase program of up to $100.0 million in common stock with no expiration, subject to factors including liquidity, credit facility compliance and market conditions.
Trupanion, Inc. reported the results of its 2026 Annual Meeting of stockholders. Shareholders elected nine directors to serve until the 2027 annual meeting, with each nominee receiving over 30.4 million votes in favor and relatively small withheld amounts.
Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 34,886,804 votes for, 53,345 against and 21,092 abstentions. In an advisory, non-binding vote, shareholders approved 2025 compensation for the company’s named executive officers, with 30,437,067 votes for, 531,314 against and 24,126 abstentions.
Trupanion reported improved results for the first quarter of 2026. Total revenue was $384.0 million, up 12% from the first quarter of 2025, driven by subscription business revenue of $269.5 million, which grew 16%. Net income was $4.9 million, or $0.11 per basic and diluted share, compared to a net loss of $1.5 million, or $(0.03) per share, a year earlier.
Adjusted EBITDA rose to $17.4 million from $12.2 million. Subscription enrolled pets reached 1,105,783 at March 31, 2026, a 5% increase over March 31, 2025, while total enrolled pets across all segments declined 2% to 1,637,665. Operating cash flow was $14.6 million and free cash flow was $13.7 million. The company held $383.7 million in cash and short-term investments at March 31, 2026.
Trupanion, Inc. announced that director Max Brodén has informed the company he will not stand for re-election at the Annual Stockholders’ Meeting scheduled for June 10, 2026 at 9 a.m. Pacific Time. His decision is for personal reasons and is not due to any disagreement with Trupanion or its Board.
Brodén plans to continue serving as a director until the 2026 Annual Meeting. The company states that his departure does not affect the strategic partnership between Aflac and Trupanion, and that Aflac remains a committed, aligned shareholder. Trupanion also furnished a shareholder letter included in its 2025 Annual Report under Regulation FD, clarifying that this information is furnished rather than filed under securities laws.
Trupanion reported strong fourth quarter and full-year 2025 results, highlighted by a return to solid profitability and double-digit growth. For 2025, total revenue reached $1,439.3 million, up 12% year over year, with subscription business revenue rising 16% to $989.3 million.
The company generated full-year net income of $19.4 million, or $0.45 per basic and diluted share, compared to a net loss of $9.6 million in 2024, including a $7.8 million realized gain from a preferred stock exchange. Adjusted EBITDA increased to $70.1 million from $46.1 million, while operating cash flow rose to $89.5 million and free cash flow to $75.4 million.
In the fourth quarter, revenue was $376.9 million, up 12%, with subscription revenue of $261.4 million, up 15%. Q4 net income was $5.6 million, or $0.13 per share, and adjusted EBITDA was $21.8 million. Subscription pets enrolled grew 5% to 1,096,173 at December 31, 2025, while total enrolled pets across all segments declined 2% to 1,647,565. Management noted achieving its 15% annual margin target and more than $150 million of discretionary profit in 2025.
Trupanion entered a new secured credit agreement with PNC Bank, adding a $100.0 million term loan and a $20.0 million revolving facility maturing on November 4, 2028. The company immediately borrowed $100.0 million under the term loan and $15.0 million from the revolver, primarily to repay its 2022 credit agreement, which was simultaneously terminated.
Loans bear interest at SOFR plus 2.75% per year. The term loan requires quarterly principal payments of $2.5 million. Trupanion may prepay or reduce commitments at any time without premium or penalty. The facilities are secured by substantially all assets and include financial covenants limiting indebtedness, liens, investments, and mergers. An event of default allows lenders to terminate revolving commitments and accelerate amounts due. Trupanion also furnished a press release for its quarter ended September 30, 2025.
Trupanion appointed Bradley S. Powell to its board of directors. Powell, 65, is an independent director under Nasdaq rules and brings extensive public-company finance experience. He served as Chief Financial Officer of Expeditors International from 2008 to 2025 and previously was CFO of Eden Bioscience from 1998 to 2008, where he led its 2000 IPO.
Powell will serve until the 2026 annual meeting of stockholders. He has no arrangements related to his appointment, no family relationships with Trupanion’s leadership, and no material interests in related-party transactions. Trupanion entered into its standard indemnification agreement with him, and he will participate in the Compensation Program for Non-Employee Directors.